Patents by Inventor Ian Kirby

Ian Kirby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHLEBOTOMY NEEDLE DESTRUCTION
    Publication number: 20210220569
    Abstract: An apparatus for processing a phlebotomy needle having a double-ended needle with a hub between its tips. The apparatus has a clamping electrode for contacting/clamping one end of the needle between the hub and tip and a tip electrode for contacting the needle at its tip. A voltage is applied between the clamping electrode and the tip electrode, to soften/melt the needle via resistive heating, at the same time as the tip electrode is advanced to compress the needle tip and blunt it. The apparatus includes means for allowing the needle to be rotated through so that the first tip and the second tip can be blunted. Also disclosed is means for detaching the needle from a main body and/or for removing a cover covering one end of the needle. The apparatus enables a Vacutainer-type needle to be disassembled into its various parts and the needle rendered blunt and non-hazardous.
    Type: Application
    Filed: July 8, 2019
    Publication date: July 22, 2021
    Inventor: Clifford Ian Kirby
  • SYRINGE DESTRUCTION
    Publication number: 20210187206
    Abstract: An apparatus for destroying syringes-needle assemblies is disclosed, the invention comprising a cradle for holding the syringe and a hub grip for gripping the hub of a needle affixed to the syringe. The apparatus comprises means for destroying the needle for example, by passing a current through it to soften/melt it, whilst at the same time, applying an axial compressive force to blunt and compress the needle. The hub grip is moveable relative to the cradle so that the needle can be pulled, unscrewed or otherwise detached from the syringe. The apparatus is preferably automated, and thus enables the destroyed needle and syringe to be separated, and therefore disposed of in separate waste streams without manual intervention.
    Type: Application
    Filed: July 8, 2019
    Publication date: June 24, 2021
    Inventor: Clifford Ian Kirby
  • ANTIBODIES, USES & METHODS
    Publication number: 20210087287
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 25, 2021
    Applicant: Kymab Limited
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
    Publication number: 20210017270
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 21, 2021
    Inventors: Gary Peter BEMBRIDGE, Chun-wa CHUNG, Susannah Karen FORD, Ian KIRBY, Ruth MCADAM, Maria FEENEY
  • Antigen binding proteins to oncostatin M (OSM)
    Patent number: 10808029
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • MULTISPECIFIC ANTIBODY WITH COMBINATION THERAPY FOR IMMUNO-ONCOLOGY
    Publication number: 20200190191
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: December 19, 2017
    Publication date: June 18, 2020
    Inventors: Jamie Iain CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • Anti-OX40L antibodies and methods of treating graft versus host disease
    Patent number: 10669342
    Abstract: The present invention relates to anti-human OX4OL antibodies, new medical uses and methods.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: June 2, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • Methods of treating SLE with anti-OX40L antibodies
    Patent number: 10654935
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: May 19, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • ANTIBODIES
    Publication number: 20200131267
    Abstract: The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2018
    Publication date: April 30, 2020
    Inventors: Joana de Abreu CARVALHO, Rachael Jane KIMBER, Jamie Ian CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE, Stephen Douglas GILLIES
  • Antibodies and immunocytokines
    Patent number: 10604576
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: March 31, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • ANTI-PD-L1 AND IL-2 CYTOKINES
    Publication number: 20190338032
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2017
    Publication date: November 7, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, IAN KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stphen Douglas GILLIES
  • ANTI-ICOS ANTIBODIES
    Publication number: 20190330345
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: August 9, 2017
    Publication date: October 31, 2019
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20190330351
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 31, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES
  • ANTIBODIES, USES & METHODS
    Publication number: 20190276547
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: November 13, 2018
    Publication date: September 12, 2019
    Applicant: Kymab Limited
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • MULTISPECIFIC ANTIBODIES FOR IMMUNO-ONCOLOGY
    Publication number: 20190202917
    Abstract: Multispecific antibody having a binding site for ICOS and a binding site for a second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours.
    Type: Application
    Filed: June 20, 2017
    Publication date: July 4, 2019
    Inventors: Jamie CAMPBELL, Nikole SANDY, Cassandra VAN KRINKS, Stephen John ARKINSTALL, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen Douglas GILLIES, Matthew John MCCOURT, Richard Charles Alfred SAINSON, Mohammed Hanif ALI, E-Chiang LEE
  • Anti-LIGHT antibodies
    Patent number: 10259880
    Abstract: The present invention relates to anti-human LIGHT antibodies, new medical uses and methods.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: April 16, 2019
    Assignee: KYMAB LIMITED
    Inventors: Jamie Iain Campbell, Bettina Franz, Steve Holmes, Ian Kirby, Anais Legent
  • Anti-ICOS antibodies
    Patent number: 9957323
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: May 1, 2018
    Assignee: Kymab Limited
    Inventors: Richard Charles Alfred Sainson, Stephen John Arkinstall, Jamie Iain Campbell, Mohammed Hanif Ali, E-Chiang Lee, Matthew John McCourt, Nikole Sandy, Cassandra Van Krinks, Volker Germaschewski, Ian Kirby, Miha Kosmac, Thomas Gallagher, Cecilia Deantonio, Stephen D. Gillies
  • ANTI-ICOS ANTIBODIES
    Publication number: 20180066058
    Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.
    Type: Application
    Filed: September 7, 2017
    Publication date: March 8, 2018
    Inventors: Richard Charles Alfred SAINSON, Stephen John ARKINSTALL, Jamie Iain CAMPBELL, Mohammed Hanif ALI, E-Chiang LEE, Matthew John MCCOURT, Nikole SANDY, Cassandra VAN KRINKS, Volker GERMASCHEWSKI, Ian KIRBY, Miha KOSMAC, Thomas GALLAGHER, Cecilia DEANTONIO, Stephen D. GILLIES
  • Synergistic combinations of OX40L antibodies for the treatment of GvHD
    Patent number: 9868790
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: January 16, 2018
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • Synergistic combinations of OX40L antibodies for the treatment of GvHD
    Patent number: 9868789
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: January 16, 2018
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell